4//SEC Filing
Fairman Jeff 4
Accession 0001209191-21-071376
CIK 0001649094other
Filed
Dec 27, 7:00 PM ET
Accepted
Dec 28, 4:15 PM ET
Size
12.3 KB
Accession
0001209191-21-071376
Insider Transaction Report
Form 4
Vaxcyte, Inc.PCVX
Fairman Jeff
VP, Research
Transactions
- Sale
Common Stock
2021-12-27$24.08/sh−175$4,214→ 6,160 total - Exercise/Conversion
Common Stock
2021-12-27$1.79/sh+4,750$8,503→ 10,910 total - Exercise/Conversion
Stock Option (right to buy)
2021-12-27−4,750→ 53,345 totalExercise: $1.79Exp: 2027-05-17→ Common Stock (4,750 underlying) - Sale
Common Stock
2021-12-27$23.58/sh−4,575$107,878→ 6,335 total
Holdings
- 341,227(indirect: By Trust)
Common Stock
- 50,000(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported is a weighted-average price. The shares were sold at prices ranging from $23.02 to $24.005. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted-average price. The shares were sold at prices ranging from $24.04 to $24.285. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]The shares subject to the option are fully vested and exercisable.
Documents
Issuer
Vaxcyte, Inc.
CIK 0001649094
Entity typeother
Related Parties
1- filerCIK 0001813800
Filing Metadata
- Form type
- 4
- Filed
- Dec 27, 7:00 PM ET
- Accepted
- Dec 28, 4:15 PM ET
- Size
- 12.3 KB